CSL Of Australia Begins First Clinical Trials For H1N1 Flu Vaccine
This article was originally published in PharmAsia News
Australia's CSL said human clinical trials have begun for its H1N1 flu virus, the first test to last seven weeks. The first batches are earmarked for Australia, Singapore and the United States, all of which have placed orders. French drug maker Sanofi-Aventis, as well as the World Health Organization, are expected to keep a close eye on the CSL trials for indications of how other H1N1 vaccine candidates might perform. An analyst noted there is little commercial advantage for a company to be the first in clinical trials for this vaccine, since so many governments have orders with several companies. (Click here for more
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.